Karami Masoumeh, Mousavi Seyyed Hossein, Rafiee Mohammad, Heidari Reza, Shahrokhi Seyedeh Zahra
Department of Biochemistry, School of Medicine, AJA University of Medical Sciences, Tehran, Iran.
Department of Cardiology, School of Medicine, AJA University of Medical Sciences, Tehran, Iran.
Diabetol Metab Syndr. 2023 Jan 11;15(1):5. doi: 10.1186/s13098-023-00980-8.
Gestational diabetes mellitus (GDM) is the most prevalent metabolic disorder during pregnancy, causing short- and long-term complications for both mother and baby. GDM is a multifactorial disease, and it may be affected by interactions between genetic, epigenetic, and environmental factors. However, the exact etiology is poorly understood. Despite the high prevalence of GDM, there is still debate regarding the optimal time for screening, the diagnostic threshold to apply, and the best strategies for treatment. Identifying effective strategies for therapeutic purposes as well as accurate biomarkers for prognostic and diagnostic purposes will reduce the GDM incidence and improve its management. In recent years, new biochemical and molecular biomarkers such as microRNAs, single-nucleotide polymorphisms, and DNA methylation have received great interest in the diagnosis of GDM. In this review, we discuss current and future diagnostic approaches for the detection of GDM and evaluate lifestyle and pharmacological strategies for GDM prevention.
妊娠期糖尿病(GDM)是孕期最常见的代谢紊乱疾病,会给母婴带来短期和长期并发症。GDM是一种多因素疾病,可能受遗传、表观遗传和环境因素之间相互作用的影响。然而,其确切病因尚不清楚。尽管GDM的患病率很高,但关于筛查的最佳时间、适用的诊断阈值以及最佳治疗策略仍存在争议。确定用于治疗目的的有效策略以及用于预后和诊断目的的准确生物标志物将降低GDM的发病率并改善其管理。近年来,微小RNA、单核苷酸多态性和DNA甲基化等新的生化和分子生物标志物在GDM的诊断中受到了极大关注。在这篇综述中,我们讨论了当前和未来检测GDM的诊断方法,并评估了GDM预防的生活方式和药物策略。